{"id":816608,"date":"2025-02-24T07:49:17","date_gmt":"2025-02-24T12:49:17","guid":{"rendered":"https:\/\/www.marketnewsdesk.com\/index.php\/monte-rosa-therapeutics-to-present-at-the-td-cowen-45th-annual-health-care-conference\/"},"modified":"2025-02-24T07:49:17","modified_gmt":"2025-02-24T12:49:17","slug":"monte-rosa-therapeutics-to-present-at-the-td-cowen-45th-annual-health-care-conference","status":"publish","type":"post","link":"https:\/\/www.marketnewsdesk.com\/index.php\/monte-rosa-therapeutics-to-present-at-the-td-cowen-45th-annual-health-care-conference\/","title":{"rendered":"Monte Rosa Therapeutics to Present at the TD Cowen 45th Annual Health Care Conference"},"content":{"rendered":"
\n

BOSTON, Feb. 24, 2025 (GLOBE NEWSWIRE) — Monte Rosa Therapeutics, Inc.<\/u><\/a> (Nasdaq: GLUE), a clinical-stage biotechnology company developing novel molecular glue degrader (MGD)-based medicines, today announced that Markus Warmuth, M.D., Chief Executive Officer, will present at the TD Cowen 45th Annual Health Care Conference on Monday, March 3, 2025, at 2:30 p.m. EST.<\/p>\n

A webcast of the presentation will be accessible via the \u201cEvents & Presentations\u201d section of Monte Rosa\u2019s website at ir.monterosatx.com<\/a>, and an archived version will be made available for 30 days following the presentation.<\/p>\n

\n About Monte Rosa<\/strong>
\n
Monte Rosa Therapeutics is a clinical-stage biotechnology company developing highly selective molecular glue degrader (MGD) medicines for patients living with serious diseases in the areas of oncology, autoimmune and inflammatory diseases, and more. MGDs are small molecule protein degraders that have the potential to treat many diseases that other modalities, including other degraders, cannot. Monte Rosa\u2019s QuEEN\u2122 (Quantitative and Engineered Elimination of Neosubstrates) discovery engine combines AI-guided chemistry, diverse chemical libraries, structural biology, and proteomics to identify degradable protein targets and rationally design MGDs with unprecedented selectivity. The QuEEN discovery engine enables access to a wide-ranging and differentiated target space of well-validated biology across multiple therapeutic areas. Monte Rosa has developed the industry\u2019s leading pipeline of MGDs, which spans oncology, autoimmune and inflammatory disease and beyond. Monte Rosa has a global license agreement with Novartis to advance VAV1-directed molecular glue degraders and a strategic collaboration with Roche to discover and develop MGDs against targets in cancer and neurological diseases previously considered impossible to drug. For more information, visit www.monterosatx.com<\/a>.<\/p>\n

\n Investors<\/strong>
\n
Andrew Funderburk
ir@monterosatx.com<\/a><\/u><\/p>\n

\n Media<\/strong>
\n
Cory Tromblee, Scient PR
media@monterosatx.com<\/a><\/u><\/p>\n

\"\"
\n
\n \"\"\n <\/div>\n

<\/div>\n","protected":false},"excerpt":{"rendered":"

BOSTON, Feb. 24, 2025 (GLOBE NEWSWIRE) — Monte Rosa Therapeutics, Inc. (Nasdaq: GLUE), a clinical-stage biotechnology company developing novel molecular glue degrader (MGD)-based medicines, today announced that Markus Warmuth, M.D., Chief Executive Officer, will present at the TD Cowen 45th Annual Health Care Conference on Monday, March 3, 2025, at 2:30 p.m. EST. A webcast of the presentation will be accessible via the \u201cEvents & Presentations\u201d section of Monte Rosa\u2019s website at ir.monterosatx.com, and an archived version will be made available for 30 days following the presentation. About Monte Rosa Monte Rosa Therapeutics is a clinical-stage biotechnology company developing highly selective molecular glue degrader (MGD) medicines for patients living with serious diseases in the areas of oncology, autoimmune and inflammatory … <\/p>\n

Continue reading “Monte Rosa Therapeutics to Present at the TD Cowen 45th Annual Health Care Conference”<\/span><\/a><\/p>\n","protected":false},"author":2,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[],"tags":[],"class_list":["post-816608","post","type-post","status-publish","format-standard","hentry"],"yoast_head":"\nMonte Rosa Therapeutics to Present at the TD Cowen 45th Annual Health Care Conference - Market Newsdesk<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.marketnewsdesk.com\/index.php\/monte-rosa-therapeutics-to-present-at-the-td-cowen-45th-annual-health-care-conference\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Monte Rosa Therapeutics to Present at the TD Cowen 45th Annual Health Care Conference - Market Newsdesk\" \/>\n<meta property=\"og:description\" content=\"BOSTON, Feb. 24, 2025 (GLOBE NEWSWIRE) — Monte Rosa Therapeutics, Inc. (Nasdaq: GLUE), a clinical-stage biotechnology company developing novel molecular glue degrader (MGD)-based medicines, today announced that Markus Warmuth, M.D., Chief Executive Officer, will present at the TD Cowen 45th Annual Health Care Conference on Monday, March 3, 2025, at 2:30 p.m. EST. A webcast of the presentation will be accessible via the \u201cEvents & Presentations\u201d section of Monte Rosa\u2019s website at ir.monterosatx.com, and an archived version will be made available for 30 days following the presentation. About Monte Rosa Monte Rosa Therapeutics is a clinical-stage biotechnology company developing highly selective molecular glue degrader (MGD) medicines for patients living with serious diseases in the areas of oncology, autoimmune and inflammatory … Continue reading "Monte Rosa Therapeutics to Present at the TD Cowen 45th Annual Health Care Conference"\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.marketnewsdesk.com\/index.php\/monte-rosa-therapeutics-to-present-at-the-td-cowen-45th-annual-health-care-conference\/\" \/>\n<meta property=\"og:site_name\" content=\"Market Newsdesk\" \/>\n<meta property=\"article:published_time\" content=\"2025-02-24T12:49:17+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTM4MzEyNyM2Nzc0Mjg4IzIyMDk1NDU=\" \/>\n<meta name=\"author\" content=\"Newsdesk\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Newsdesk\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"1 minute\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/monte-rosa-therapeutics-to-present-at-the-td-cowen-45th-annual-health-care-conference\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/monte-rosa-therapeutics-to-present-at-the-td-cowen-45th-annual-health-care-conference\\\/\"},\"author\":{\"name\":\"Newsdesk\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"headline\":\"Monte Rosa Therapeutics to Present at the TD Cowen 45th Annual Health Care Conference\",\"datePublished\":\"2025-02-24T12:49:17+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/monte-rosa-therapeutics-to-present-at-the-td-cowen-45th-annual-health-care-conference\\\/\"},\"wordCount\":292,\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/monte-rosa-therapeutics-to-present-at-the-td-cowen-45th-annual-health-care-conference\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=OTM4MzEyNyM2Nzc0Mjg4IzIyMDk1NDU=\",\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/monte-rosa-therapeutics-to-present-at-the-td-cowen-45th-annual-health-care-conference\\\/\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/monte-rosa-therapeutics-to-present-at-the-td-cowen-45th-annual-health-care-conference\\\/\",\"name\":\"Monte Rosa Therapeutics to Present at the TD Cowen 45th Annual Health Care Conference - Market Newsdesk\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/monte-rosa-therapeutics-to-present-at-the-td-cowen-45th-annual-health-care-conference\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/monte-rosa-therapeutics-to-present-at-the-td-cowen-45th-annual-health-care-conference\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=OTM4MzEyNyM2Nzc0Mjg4IzIyMDk1NDU=\",\"datePublished\":\"2025-02-24T12:49:17+00:00\",\"author\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"breadcrumb\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/monte-rosa-therapeutics-to-present-at-the-td-cowen-45th-annual-health-care-conference\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/monte-rosa-therapeutics-to-present-at-the-td-cowen-45th-annual-health-care-conference\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/monte-rosa-therapeutics-to-present-at-the-td-cowen-45th-annual-health-care-conference\\\/#primaryimage\",\"url\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=OTM4MzEyNyM2Nzc0Mjg4IzIyMDk1NDU=\",\"contentUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=OTM4MzEyNyM2Nzc0Mjg4IzIyMDk1NDU=\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/monte-rosa-therapeutics-to-present-at-the-td-cowen-45th-annual-health-care-conference\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Monte Rosa Therapeutics to Present at the TD Cowen 45th Annual Health Care Conference\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\",\"name\":\"Market Newsdesk\",\"description\":\"Latest Business News in Real Time\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\",\"name\":\"Newsdesk\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"caption\":\"Newsdesk\"},\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/author\\\/newsdesk\\\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Monte Rosa Therapeutics to Present at the TD Cowen 45th Annual Health Care Conference - Market Newsdesk","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.marketnewsdesk.com\/index.php\/monte-rosa-therapeutics-to-present-at-the-td-cowen-45th-annual-health-care-conference\/","og_locale":"en_US","og_type":"article","og_title":"Monte Rosa Therapeutics to Present at the TD Cowen 45th Annual Health Care Conference - Market Newsdesk","og_description":"BOSTON, Feb. 24, 2025 (GLOBE NEWSWIRE) — Monte Rosa Therapeutics, Inc. (Nasdaq: GLUE), a clinical-stage biotechnology company developing novel molecular glue degrader (MGD)-based medicines, today announced that Markus Warmuth, M.D., Chief Executive Officer, will present at the TD Cowen 45th Annual Health Care Conference on Monday, March 3, 2025, at 2:30 p.m. EST. A webcast of the presentation will be accessible via the \u201cEvents & Presentations\u201d section of Monte Rosa\u2019s website at ir.monterosatx.com, and an archived version will be made available for 30 days following the presentation. About Monte Rosa Monte Rosa Therapeutics is a clinical-stage biotechnology company developing highly selective molecular glue degrader (MGD) medicines for patients living with serious diseases in the areas of oncology, autoimmune and inflammatory … Continue reading \"Monte Rosa Therapeutics to Present at the TD Cowen 45th Annual Health Care Conference\"","og_url":"https:\/\/www.marketnewsdesk.com\/index.php\/monte-rosa-therapeutics-to-present-at-the-td-cowen-45th-annual-health-care-conference\/","og_site_name":"Market Newsdesk","article_published_time":"2025-02-24T12:49:17+00:00","og_image":[{"url":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTM4MzEyNyM2Nzc0Mjg4IzIyMDk1NDU=","type":"","width":"","height":""}],"author":"Newsdesk","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Newsdesk","Est. reading time":"1 minute"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/monte-rosa-therapeutics-to-present-at-the-td-cowen-45th-annual-health-care-conference\/#article","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/monte-rosa-therapeutics-to-present-at-the-td-cowen-45th-annual-health-care-conference\/"},"author":{"name":"Newsdesk","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"headline":"Monte Rosa Therapeutics to Present at the TD Cowen 45th Annual Health Care Conference","datePublished":"2025-02-24T12:49:17+00:00","mainEntityOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/monte-rosa-therapeutics-to-present-at-the-td-cowen-45th-annual-health-care-conference\/"},"wordCount":292,"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/monte-rosa-therapeutics-to-present-at-the-td-cowen-45th-annual-health-care-conference\/#primaryimage"},"thumbnailUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTM4MzEyNyM2Nzc0Mjg4IzIyMDk1NDU=","inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/monte-rosa-therapeutics-to-present-at-the-td-cowen-45th-annual-health-care-conference\/","url":"https:\/\/www.marketnewsdesk.com\/index.php\/monte-rosa-therapeutics-to-present-at-the-td-cowen-45th-annual-health-care-conference\/","name":"Monte Rosa Therapeutics to Present at the TD Cowen 45th Annual Health Care Conference - Market Newsdesk","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/monte-rosa-therapeutics-to-present-at-the-td-cowen-45th-annual-health-care-conference\/#primaryimage"},"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/monte-rosa-therapeutics-to-present-at-the-td-cowen-45th-annual-health-care-conference\/#primaryimage"},"thumbnailUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTM4MzEyNyM2Nzc0Mjg4IzIyMDk1NDU=","datePublished":"2025-02-24T12:49:17+00:00","author":{"@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"breadcrumb":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/monte-rosa-therapeutics-to-present-at-the-td-cowen-45th-annual-health-care-conference\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.marketnewsdesk.com\/index.php\/monte-rosa-therapeutics-to-present-at-the-td-cowen-45th-annual-health-care-conference\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/monte-rosa-therapeutics-to-present-at-the-td-cowen-45th-annual-health-care-conference\/#primaryimage","url":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTM4MzEyNyM2Nzc0Mjg4IzIyMDk1NDU=","contentUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTM4MzEyNyM2Nzc0Mjg4IzIyMDk1NDU="},{"@type":"BreadcrumbList","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/monte-rosa-therapeutics-to-present-at-the-td-cowen-45th-annual-health-care-conference\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/www.marketnewsdesk.com\/"},{"@type":"ListItem","position":2,"name":"Monte Rosa Therapeutics to Present at the TD Cowen 45th Annual Health Care Conference"}]},{"@type":"WebSite","@id":"https:\/\/www.marketnewsdesk.com\/#website","url":"https:\/\/www.marketnewsdesk.com\/","name":"Market Newsdesk","description":"Latest Business News in Real Time","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.marketnewsdesk.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Person","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979","name":"Newsdesk","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","caption":"Newsdesk"},"url":"https:\/\/www.marketnewsdesk.com\/index.php\/author\/newsdesk\/"}]}},"_links":{"self":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/816608","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/comments?post=816608"}],"version-history":[{"count":0,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/816608\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/media?parent=816608"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/categories?post=816608"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/tags?post=816608"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}